Bank of India Aggressive Hybrid Fund
The scheme seeks to provide capital appreciation to investors from a portfolio constituting of mid and small cap equity and equity related securities as well as fixed income securities.
Growthvine rating: 5/5 — ranked #2 of 36 in category.
Fund basics
| Category | Hybrid: Aggressive |
|---|
| NAV | ₹42.47 (as of 2026-10-05) |
|---|
| AUM | ₹2,051 Cr |
|---|
| Expense ratio | 1.76% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Alok Singh |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 3 months |
|---|
Performance & risk
| 5-year annualised return | 13.24% |
|---|
| Sharpe ratio | 0.72 |
|---|
| Standard deviation | 15.82% |
|---|
| Max drawdown | −37.83% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 147.7% of NIFTY 50 Hybrid Composite Debt 65:35 Index's upside and 105.2% of its downside.
Market cap allocation
| Large cap | 0.0% |
|---|
| Mid cap | 60.3% |
|---|
| Small cap | 39.7% |
|---|
Concentration
| Top 5 holdings | 10.9% |
|---|
| Top 10 holdings | 20.3% |
|---|
| Total holdings | 63 |
|---|
Top holdings
- TREPS — 6.6%
- Bank of maharashtra — 2.4%
- Balrampur Chini Mills Ltd. — 2.3%
- Sterlite Technologies Limited. — 2.1%
- UNO Minda Limited — 2.1%
- 7.6% Power Finance Corporation Limited (13/04/2029) — 2.0%
- Aurobindo Pharma Ltd. — 2.0%
- Federal Bank Ltd. — 2.0%
- Abbott India Ltd. — 1.9%
- Mankind Pharma Limited — 1.9%
Top sectors
Not disclosed.
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 10.0% | Q1 (Top) | #1 of 33 |
| 2025 | −0.9% | Q4 (Bottom) | #32 of 33 |
| 2024 | 25.8% | Q1 (Top) | #3 of 33 |
| 2023 | 33.7% | Q1 (Top) | #2 of 33 |
| 2022 | −4.8% | Q4 (Bottom) | #29 of 30 |